Riva E, Traquandi C
Istituto di Ricerche Farmacologiche, Mario Negri, Milan, Italy.
Eur J Pharmacol. 1996 Oct 3;312(3):293-300. doi: 10.1016/0014-2999(96)00467-0.
We assessed the effects of idrapril, a novel angiotensin-converting enzyme inhibitor, and captopril in the isolated rat heart after ischaemia and reperfusion and measured angiotensin-converting enzyme activity in myocardial tissue. Hearts were perfused and subjected to global ischaemia and reperfusion. Idrapril (0.1, 1, 10, and 50 micrograms/ml), captopril (80 micrograms/ml) or vehicle were given before ischaemia and throughout reperfusion. Post-ischaemic recovery of coronary flow was significantly decreased with 50 micrograms/ml of idrapril (43 +/- 9% compared to 64 +/- 3% in controls) whereas heart rate was unaffected. Recovery of developed pressure and activity of cardiac angiotensin-converting enzyme were significantly reduced by idrapril in a dose-dependent manner. This study suggests that protection or lack of protection by idrapril on recovery of contractile function seems to depend on the degree of inhibition of tissue angiotensin-converting enzyme activity in the setting of acute heart ischaemic insult. Our results suggest that while a certain degree of inhibition of angiotensin-converting enzyme in the heart is beneficial, marked tissue inhibition may be deleterious.
我们评估了新型血管紧张素转换酶抑制剂依那普利和卡托普利对离体大鼠心脏缺血再灌注后的影响,并测定了心肌组织中的血管紧张素转换酶活性。心脏经灌注后经历全心缺血和再灌注。在缺血前及整个再灌注过程中给予依那普利(0.1、1、10和50微克/毫升)、卡托普利(80微克/毫升)或赋形剂。50微克/毫升依那普利使缺血后冠脉血流的恢复显著降低(与对照组的64±3%相比为43±9%),而心率未受影响。依那普利以剂量依赖方式显著降低心脏血管紧张素转换酶的活性及心脏收缩压的恢复。本研究提示,依那普利对收缩功能恢复的保护或缺乏保护似乎取决于急性心脏缺血损伤情况下组织血管紧张素转换酶活性的抑制程度。我们的结果表明,虽然心脏中一定程度的血管紧张素转换酶抑制是有益的,但显著的组织抑制可能是有害的。